Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 8 | 697 | 45% |
| 2020 | 1 | 467 | 51% |
| 2021 | 2 | 535 | 55% |
| 2022 | 2 | 439 | 59% |
| 2023 | 2 | 465 | 63% |
| 2024 | 0 | 381 | 66% |
| 2025 from claims | – | 378 305–443 | 67% |
| 2026 forecast | – | 379 297–476 | 67% |
| 2027 forecast | – | 376 279–497 | 68% |
| 2028 forecast | – | 373 264–515 | 69% |
| 2029 forecast | – | 370 252–531 | 70% |
| 2030 forecast | – | 367 240–545 | 70% |
Endovascular abdominal and thoracic aortic repair. Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 3 | 615−5.9%/yr | −5.9%/yr | 0.6 | 0% | 460 in 2030−4.8%/yr |
| Illinois | 7 | 563−7.4%/yr | −7.4%/yr | 0.4 | 0% | 600 in 2030+1.1%/yr |
| Missouri | 5 | 372−9.1%/yr | −9.1%/yr | 0.6 | 0% | 340 in 2030−1.6%/yr |
| Indiana | 4 | 350−7.1%/yr | −7.1%/yr | 0.5 | 0% | 380 in 2030+1.5%/yr |
| Wisconsin | 1 | 197−8.5%/yr | −8.5%/yr | 0.4 | 0% | 270 in 2030+5.7%/yr |
| Minnesota | 0 | 187−8.9%/yr | −8.9%/yr | 0.4 | 0% | 190 in 2030+0.2%/yr |
| Kansas | 3 | 178−7.8%/yr | −7.8%/yr | 0.4 | 0% | 160 in 2030−1.9%/yr |
| Iowa | 1 | 169+0.7%/yr | +0.7%/yr | 0.4 | 0% | 210 in 2030+3.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 59 | 5,586−14%/yr | −14%/yr | 6.91.7× | 71% | 4,770 in 2030−2.6%/yr |
| Peripheral arterial intervention | 34 | 4,986−13%/yr | −13%/yr | 5.61.4× | 65% | 5,540 in 2030+1.8%/yr |
| Superficial venous ablation | 44 | 2,935−15%/yr | −15%/yr | 3.31.0× | 95% | 2,850 in 2030−0.5%/yr |
| Thrombectomy, IVC filters & venous stents | 10 | 1,534−1.8%/yr | −1.8%/yr | 1.81.4× | 18% | 1,770 in 2030+2.4%/yr |
| Carotid revascularization | 13 | 961−9.4%/yr | −9.4%/yr | 1.11.0× | 0% | 870 in 2030−1.7%/yr |
Aortic endografts (EVAR/TEVAR) in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Ohio
Medtronic leads with 47% of company spending on these surgeons in 2025, +4 pts on 2024.
In 2025, 5 companies reported engagement with Michigan’s surgeons worth $192K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.